Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003139 · ClinicalTrials.gov registry record · Phase 3
Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer
A Phase 3 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 249
- Enrollment target
NCT00003139: Completed Phase 3 study, sponsored by Radiation Therapy Oncology Group.
NCT00003139 is a Phase 3 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 249 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003139, a Phase 3 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 249 participants
- Enrollment target
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as pilocarpine may protect normal cells from the side effects of radiation therapy. It is not yet known if pilocarpine may be effective in preventing mucositis and dry mouth in patients receiving radiation therapy for head and neck cancer. PURPOSE: Randomized, double-blinded, phase III trial to study the effectiveness of pilocarpine in preventing mucositis and dry mouth in patients receiving radiation therapy for head and neck cancer.
Interventions
- OTHER Placebo
- DRUG pilocarpine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 249 participants |
| Start Date | 1998-03 |
| Est. Completion | 2002-10 |
| Phase | Phase 3 |
What the finished NCT00003139 record still lists
NCT00003139 is an interventional study that assigns participants to a tested intervention. The registered 249 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00003139 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003139 about?
NCT00003139 is a clinical study titled "Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as pilocarpine may protect normal cells from the side effects of radiation therapy. It is not yet known if pilocarpine may be effective in preventing mucositis and dry mouth in patients receiving radiation therapy...
What is the current status of trial NCT00003139?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 249 participants. The study started on 1998-03. Estimated completion is 2002-10.
What interventions are being tested in trial NCT00003139?
The interventions under investigation include: Placebo (OTHER), pilocarpine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003139?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00003139's enrollment target sits among peer trials
249 1266th of 2000 higher than 735 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04628767 · 249 participants · Phase 2
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
- NCT05834907 · 249 participants · NA
Hands and Hearts Together
- NCT06067555 · 249 participants · Early Phase 1
Intradermal Influenza Vaccination
- NCT06588478 · 249 participants · Phase 2
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia